Deka Biosciences Closes USD $20 Million Series B2 Financing Led by MPM BioImpact
Maryland-based biotech company Deka Biosciences ("Deka") announced that it has successfully closed a USD $20 Million Series B2 financing with a syndicate of life science investors led by MPM BioImpact, and joined by additional investors including Leaps by Bayer, Lumira Ventures, O-Bio (Echo Investment Capital), Viva BioInnovator, Alexandria Venture Investments, Amana Investments, Plains Ventures, ATEM Capital and CEO John Mumm.